Amir Hamrahian
Johns Hopkins University · The Cleveland Clinic
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Amir Hamrahian as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:41 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT07247058 · Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)Johns Hopkins University · recruiting · Mild Autonomous Cortisol Secretion (MACS) · principal investigator
- N/ANCT01282164 · The Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and Adrenocorticotropic AxisThe Cleveland Clinic · completed · Adult Growth Hormone Deficiency, Hypothalamic-pituitary Disorders · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:41 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.J Clin Endocrinol Metab · 2014160 citationsRCR 6.6
- Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.Pituitary · 2016122 citationsRCR 5.7
- 62 citationsRCR 3.1
- THE EVALUATION OF INCIDENTALLY DISCOVERED ADRENAL MASSES.Endocr Pract · 201959 citationsRCR 3.6
- A long-acting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults.J Clin Endocrinol Metab · 201345 citationsRCR 1.6
- Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors.Endocr Pract · 200814 citationsRCR 0.4
- 8 citationsRCR 0.5